Evidence map›Paper›PMID 38651093›Full record

ArticleResearch and practice in thrombosis and haemostasis2024

A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.

Mouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, Shruti Chaturvedi, Ana G Antun, Andrew M Farland, Ryan Woods, Ara Metjian, Yara A Park, Gustaaf de Ridder and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Tailored treatment of acute immune-mediated thrombotic thrombocytopenic purpura.Hematology. American Society of Hematology. Education Program · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Mouhamed Yazan Abou-IsmailDivision of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Chong ZhangDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Angela P PressonDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Shruti ChaturvediThe Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Ana G AntunDepartment of Medicine, Emory University, Atlanta, Georgia, USA.
Andrew M FarlandDepartment of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA.
Ryan WoodsDepartment of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA.
Ara MetjianDepartment of Medicine, University of Colorado, Denver, Colorado, USA.
Yara A ParkDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Gustaaf de RidderDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Briana GibsonDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Raj S KasthuriDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Darla K LilesDepartment of Medicine, East Carolina University, Greenville, North Carolina, USA.
Frank AkwaaDepartment of Medicine, University of Rochester, Rochester, New York, USA.
Todd CloverSt Charles Healthcare, Bend, Oregon, USA.
Lisa Baumann KreuzigerVersiti, Milwaukee, Wisconsin, USA.
Meera SridharanDepartment of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Ronald S GoDepartment of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Keith R McCraeDepartment of Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Harsh Vardhan UpretiThe Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Radhika GangarajuDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Nicole K KocherDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
X Long ZhengDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Jay S RavalDepartment of Pathology, University of New Mexico, Albuquerque, New Mexico, USA.
Camila MasiasBaptist Health South Florida, Miami, Florida, USA.
Spero R CatalandDepartment of Medicine, The Ohio State University, Columbus, Ohio, USA.
Andrew D JohnsonDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
Elizabeth DavisDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Michael D EvansClinical & Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, USA.
Marshall MazepaDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Ming Y LimDivision of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.

Funding

North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
Pathogenesis of Thrombotic MicroangiopathyR01HL126724 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHENG, X. LONG · 2015 to 2018
$1.8M
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic PurpuraR01HL144552 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHENG, X. LONG · 2019 to 2022
$1.8M
Clonal Hematopoiesis in a Biracial PopulationK08HL159290 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Radhika Gangaraju · 2022 to 2026
$820k
NCATS NIH HHS UL1 TR001111NCATS NIH HHS UL1 TR002494NCATS NIH HHS UM1 TR004406NCATS NIH HHS UM1 TR004409NHLBI NIH HHS K08 HL159290NHLBI NIH HHS R01 HL126724NHLBI NIH HHS R01 HL144552
6 · The paper itself

Abstract

Background: Mortality due to immune-mediated thrombotic thrombocytopenic purpura (iTTP) remains significant. Predicting mortality risk may potentially help individualize treatment. The French Thrombotic Microangiopathy (TMA) Reference Score has not been externally validated in the United States. Recent advances in machine learning technology can help analyze large numbers of variables with complex interactions for the development of prediction models. Objectives: To validate the French TMA Reference Score in the United States Thrombotic Microangiopathy (USTMA) iTTP database and subsequently develop a novel mortality prediction tool, the USTMA TTP Mortality Index. Methods: We analyzed variables available at the time of initial presentation, including demographics, symptoms, and laboratory findings. We developed our model using gradient boosting machine, a machine learning ensemble method based on classification trees, implemented in the R package gbm. Results: In our cohort ( Conclusion: The USTMA Mortality Index was acceptable for predicting mortality due to acute iTTP in the USTMA registry, but not sensitive enough to rule out death. Identifying patients at high risk of iTTP-related mortality may help individualize care and ultimately improve iTTP survival outcomes. Further studies are needed to provide external validation. Our model is one of many recent examples where machine learning models may show promise in clinical prediction tools in healthcare.

Indexed as

artificial intelligencemachine learningmortalitystatistical modelsthrombotic thrombocytopenic purpura

Identifiers

PMID38651093
PMCPMC11033197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.